Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431

  • Authors:
    • Kiyoshi Ohkawa
    • Tadashi Asakura
    • Katsuhiko Aoki
    • Shun-Ichi Shibata
    • Jiro Minami
    • Chieko Fujiwara
    • Tomoaki Sai
    • Hideki Marushima
    • Hirofusa Kuzuu
  • View Affiliations

  • Published online on: February 1, 2004     https://doi.org/10.3892/ijo.24.2.425
  • Pages: 425-433
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

A431 resistant variants to epoxomicin (EXM) were established, showing 4.0-6.7 times more resistance to EXM than parental A431P. Both variants demonstrated increased expression of the β-subunit molecules of 26S proteasome with approximately 2.5 times increased activity. In variant cells, cyclin B and P34cdc2 were over-expressed, whereas P21WAF1 was expressed at a similar level to A431P. Because of the proteasome inhibitor acting as a G2/M blocker, results are to the advantage of resistant cells proliferating in the presence of an inhibitor under a severe environment. Variant cells showed increased expression of epidermal growth factor receptor (EGFR) and decreased expression of mRNA, but also slight accumulation of protein of c-Cbl, which is a negative regulator of EGFR possessing ubiquitin ligase activity to desensitize EGF signaling. UbcH7, acting intimately with c-Cbl, was decreased in level compared to A431P. These phenomena can be regarded as one of the causes of prevention of c-Cbl-mediated down-regulation of EGFR in variant cells, enabling them to live. The anti-apoptotic Bcl-2 mainly consisted of a phosphorylated form with resistance to proteasomal degradation, suggesting that Bcl-2 phosphorylation occurred independently of its apoptotic function. Variant cells showed resistance not only to EXM, but to the 5 proteasome inhibitors, while demonstrating collateral sensitivity to doxorubicin.

Related Articles

Journal Cover

February 2004
Volume 24 Issue 2

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Ohkawa K, Asakura T, Aoki K, Shibata S, Minami J, Fujiwara C, Sai T, Marushima H and Kuzuu H: Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431. Int J Oncol 24: 425-433, 2004
APA
Ohkawa, K., Asakura, T., Aoki, K., Shibata, S., Minami, J., Fujiwara, C. ... Kuzuu, H. (2004). Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431. International Journal of Oncology, 24, 425-433. https://doi.org/10.3892/ijo.24.2.425
MLA
Ohkawa, K., Asakura, T., Aoki, K., Shibata, S., Minami, J., Fujiwara, C., Sai, T., Marushima, H., Kuzuu, H."Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431". International Journal of Oncology 24.2 (2004): 425-433.
Chicago
Ohkawa, K., Asakura, T., Aoki, K., Shibata, S., Minami, J., Fujiwara, C., Sai, T., Marushima, H., Kuzuu, H."Establishment and some characteristics of epoxomicin (a proteasome inhibitor) resistant variants of the human squamous cell carcinoma cell line, A431". International Journal of Oncology 24, no. 2 (2004): 425-433. https://doi.org/10.3892/ijo.24.2.425